At a time when equities, currencies and commodities are losing ground, Wockhardt’s stock has delivered amazing returns which are praiseworthy given that, not long ago, the company was in the doldrums.
Wockhardt Limited has rallied 6% to Rs 762, also its lifetime high, in an other wise weak market, after reporting a 57% year-on-year (y-o-y) growth in operating profit at Rs 429 crore for the quarter ended March 2012. Operating margins of the
Wockhardt is trading 4% higher as compared to its previous close, bouncing back 10% from its intra-day low, after reporting a strong 58% year-on-year (y-o-y) growth in operating profit at Rs 429 crore for the quarter ended March 2012. Net
Lehman Brothers Special Financing (LBSF) has withdrawn its winding up petition against Mumbai-based Wockhardt. Following the withdrawal, the hurdle for selling Wockhardt's nutrition business to Danone has been cleared.
Wockhardt is trading higher by 5.4% at Rs 467 on reporting 51% year-on-year (yoy) growth in net profit at Rs 213 crore for the third quarter ended December 2011, on the back of strong sales in the US market.
Drug firm Wockhardt Ltd today said its consolidated net profit rose by 50.21 per cent to Rs 212.81 crore in the third quarter ended December 31, 2011, on the back of strong sales in the US market.
Shares of pharmaceutical companies are in limelight in otherwise subdued market in morning trades after a global rating agency Fitch said its outlook on India's pharmaceutical sector for 2012 remains stable, as earnings prospects are expected to remain
The high court here on Tuesday ruled there was no injunction against the bondholders moving a UK court against the foreign currency convertible bond (FCCB) default of pharma major Wockhardt.
Wockhardt has soared 13% to Rs 343, extending its Tuesday 3% gain, after the company said it has received final approval from the US health regulator to market generic Fluticasone nasal spray used for treating allergic nasal inflammation in the American
Drug firm Wockhardt today said it has received final approval from the US health regulator to market generic Fluticasone nasal spray, used for treating allergic nasal inflammation, in the American market.
Pharmaceutical and biotechnology firm Wockhardt today received a final approval from the US Food and Drug Administration (USFDA) for marketing 50 mcg nasal spray of Fluticasone, the company said in a release filed with the Bombay Stock Exchange (BSE).
Wockhardt has moved higher by 4% at Rs 308 after the pharmaceutical company said that it has received final approval from the USFDA for marketing nasal spray of Fluticasone which is used in treatment of allergic rhinitis.
Wockhardt has plunged 11% to Rs 271, extending Monday’s 10% fall, on concerns that it will face increased competition for sale of generic Toprol, after Mylan received an approval to sell the drug in the US.
The high court here on Friday granted foreign currency convertible bond (FCCB) holders more time to respond to an anti-suit injunction filed by pharma major Wockhardt.
Wockhardt is trading higher by 4% to Rs 429 after reporting a consolidated net profit of Rs 128 crore for the second quarter ended September 30, 2011, as against a net loss of Rs 97 crore in a year ago quarter.
Drug firm Wockhardt today reported a consolidated net profit of Rs 127.58 crore for the second quarter ended September 30, 2011 on improved sales in all markets led by the US.
Wockhardt has rallied 11% to Rs 445 on reports that the company has agreed to settle a case filed by creditors regarding the repayment of foreign currency convertible bonds (FCCB).
The High Court had last week granted an additional one week's time to the debt-ridden Wockhardt to arrive at a workable solution to handle the litigations from its foreign debtors.
